rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ENGN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      EnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND Data
      Nov 14Yahoo FinanceENGN
      enGene: Downgrading To 'Sell' On Non-Competitive Efficacy Detalimogene For NMIBC
      Nov 13Seeking AlphaENGN
      enGene rises after mid-stage trial data for bladder cancer therapy; Piper upgrades

      enGene Therapeutics (ENGN) stock rose as Piper Sandler upgraded the company following updated mid-stage trial data for its lead asset, detalimogene. Read more here.

      Nov 12Seeking AlphaENGNPIPR
      Why is enGene Therapeutics stock rallying today?
      Nov 12Investing.comENGN
      Engene stock maintains Outperform rating on bladder cancer data
      Nov 12Investing.comENGN
      enGene reports improved efficacy data for bladder cancer therapy
      Nov 11Investing.comENGN
      enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC
      Nov 11Yahoo FinanceENGN
      enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones
      Nov 11Yahoo FinanceENGN
      enGene to Participate in Upcoming Investor Conferences
      Nov 6Yahoo FinanceENGN
      enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow (NASDAQ:ENGN) 2026-10-19
      Oct 19Seeking AlphaENGN
      H.C. Wainwright reiterates Engene stock rating on NMIBC data
      Oct 16Investing.comENGN
      enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
      Oct 16Yahoo FinanceENGN
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN)

      Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailENGN
      enGene at Morgan Stanley conference: bladder cancer push gains momentum
      Sep 14Investing.comENGNMS
      enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
      Sep 10Seeking AlphaENGN
      Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

      Detailed price information for Engene Therapeutics Inc (ENGN-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailENGNGPCR
      Engene Holdings stock rating maintained at Market Perform by Citizens
      Sep 9Investing.comENGN
      enGene at Wells Fargo conference: bladder cancer push gains focus
      Sep 8Investing.comENGNWFC
      enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

      BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.

      Sep 8Yahoo FinanceENGN
      enGene to Participate in Upcoming Investor Conferences

      BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:

      Sep 1Yahoo FinanceENGN

      This is the newest page. Registered accounts read further back.